Trials that use: Score-based CI for proportions (Miettinen-Nurminen, Newcombe, Wilson)
New to this method? Read the tutorial →
10 results
- KEYNOTE-010Independent statistical analysis of KEYNOTE-010, including its randomized phase 2/3 design, overall survival, progression-free survival, response, safety, statistical methods, and interpretation.
- KEYNOTE-189Independent statistical analysis of KEYNOTE-189 (NCT02578680), a randomized phase 3 trial evaluating pembrolizumab with pemetrexed-platinum chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
- KEYNOTE-240Independent statistical analysis of KEYNOTE-240, a randomized phase 3 trial of pembrolizumab plus best supportive care versus placebo plus best supportive care in previously systemically treated advanced hepatocellular carcinoma.
- KEYNOTE-394Independent statistical analysis of KEYNOTE-394, a randomized phase 3 trial of pembrolizumab or placebo with best supportive care in Asian participants with previously treated advanced hepatocellular carcinoma.
- KEYNOTE-671Independent statistical analysis of KEYNOTE-671, a randomized phase 3 trial of pembrolizumab with platinum-doublet chemotherapy as neoadjuvant/adjuvant therapy for resectable stage II, IIIA, and resectable IIIB non-small cell lung cancer.
- KEYNOTE-A18Independent statistical analysis of KEYNOTE-A18 (NCT04221945), a randomized phase 3 trial of chemoradiotherapy with or without pembrolizumab in locally advanced cervical cancer, including primary time-to-event results, secondary endpoints, cLDA, stratified analysis, and…
- MOVe-AHEADIndependent statistical analysis of the phase 3 MOVe-AHEAD trial of molnupiravir for prevention of Coronavirus Disease (COVID-19) in adults, including endpoint definitions, score-based confidence intervals, reported results, safety, and statistical interpretation.
- TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.
- VERTIS CVIndependent statistical analysis of VERTIS CV (NCT01986881): a stratified Cox non-inferiority analysis of ertugliflozin versus placebo for MACE with a 1.3 hazard-ratio margin, cLDA analyses of A1C change in glycemic sub-studies, secondary…
- VICTORIAIndependent statistical analysis of the VICTORIA phase 3 trial of vericiguat versus placebo in participants with heart failure with reduced ejection fraction, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety,…